We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+25.89%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$123M
AUM Growth
+$4.73M
Cap. Flow
-$17.5M
Cap. Flow %
-14.2%
Top 10 Hldgs %
61.58%
Holding
49
New
16
Increased
11
Reduced
12
Closed
8

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$2.84M
2
CMPS
Compass Pathways
CMPS
+$2.73M
3
INSM icon
Insmed
INSM
+$2.61M
4
MREO
Mereo BioPharma
MREO
+$2.41M
5
PCVX icon
Vaxcyte
PCVX
+$2.25M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$13M
2
DYN icon
Dyne Therapeutics
DYN
+$6.62M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$5.78M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$4.34M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$3.39M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$7.73B
$15.5M 12.53%
135,400
+25,000
+23% +$2.25M
OCUL icon
2
Ocular Therapeutix
OCUL
$1.84B
$10.4M 8.39%
1,190,071
-1,581,059
-57% -$13M
TRML
3
DELISTED
Tourmaline Bio
TRML
$8.54M 6.92%
332,095
+62,481
+23% +$1.04M
INSM icon
4
Insmed
INSM
$21.3B
$7.85M 6.36%
107,500
+35,400
+49% +$2.61M
ELVN icon
5
Enliven Therapeutics
ELVN
$4.15B
$7.57M 6.13%
296,368
-101,330
-25% -$2.35M
CRNX icon
6
Crinetics Pharmaceuticals
CRNX
$8.87B
$6.73M 5.45%
131,700
-3,441
-3% -$177K
ACLX
7
DELISTED
Arcellx
ACLX
$5.19M 4.2%
62,100
+19,900
+47% +$1.33M
MREO
8
Mereo BioPharma
MREO
$50.4M
$5.18M 4.2%
1,260,700
+583,700
+86% +$2.41M
RVMD icon
9
Revolution Medicines
RVMD
$38.8B
$4.9M 3.97%
108,000
-25,000
-19% -$1.09M
TSHA icon
10
Taysha Gene Therapies
TSHA
$1.66B
$4.26M 3.45%
2,118,992
-211,945
-9% -$465K
TERN
11
DELISTED
Terns Pharmaceuticals
TERN
$4.06M 3.29%
487,000
+117,720
+32% +$969K
KURA icon
12
Kura Oncology
KURA
$816M
$3.85M 3.12%
197,000
+34,000
+21% +$689K
WHWK
13
Whitehawk Therapeutics
WHWK
$196M
$3.81M 3.09%
1,849,402
– –
RCKT icon
14
Rocket Pharmaceuticals
RCKT
$372M
$3.51M 2.84%
190,000
-60,370
-24% -$1.24M
PRAX icon
15
Praxis Precision Medicines
PRAX
$8.52B
$3.31M 2.68%
57,500
-106,931
-65% -$5.78M
ARGX icon
16
argenx
ARGX
$52B
$3.2M 2.59%
5,900
+1,900
+48% +$960K
ASND icon
17
Ascendis Pharma A/S
ASND
$16B
$3.14M 2.54%
+21,000
New +$2.84M
CMPS
18
Compass Pathways
CMPS
$1.52B
$2.43M 1.97%
+386,500
New +$2.73M
MRSN
19
DELISTED
Mersana Therapeutics
MRSN
$2.27M 1.84%
48,000
-18,520
-28% -$817K
BBOT
20
BridgeBio Oncology
BBOT
$661M
$1.89M 1.53%
180,945
+3,109
+2% +$32.2K
SLRN
21
DELISTED
ACELYRIN
SLRN
$1.79M 1.45%
+364,000
New +$1.88M
EWTX icon
22
Edgewise Therapeutics
EWTX
$4.13B
$1.68M 1.36%
+63,000
New +$1.25M
DYN icon
23
Dyne Therapeutics
DYN
$4.71B
$1.66M 1.34%
46,200
-166,300
-78% -$6.62M
GILD icon
24
Gilead Sciences
GILD
$163B
$1.63M 1.32%
+19,500
New +$1.49M
RARE icon
25
Ultragenyx Pharmaceutical
RARE
$2.46B
$1.39M 1.13%
+25,100
New +$1.28M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Acuta Capital Partners held 49 positions worth $123M, up 4% from $119M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Acuta Capital Partners withdrew a net $17.5M in Q3 2024, closing 8 positions and reducing 12 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $4.34M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Ascendis Pharma A/S worth $3.14M.

  • Acuta Capital Partners's largest Q3 2024 buy was Ascendis Pharma A/S: 21,000 shares worth $3.14M.
  • Acuta Capital Partners added most to Insmed in Q3 2024, an estimated $2.61M increase.
  • Acuta Capital Partners's biggest Q3 2024 reduction was Ocular Therapeutix, cutting an estimated $13M.
  • Acuta Capital Partners fully exited Sarepta Therapeutics in Q3 2024, selling an estimated $4.34M.
  • Acuta Capital Partners's ten largest holdings make up 62% of its $123M portfolio in Q3 2024.
  • Acuta Capital Partners opened 16 new positions and closed 8 in Q3 2024.
  • Acuta Capital Partners's portfolio value rose 4% quarter-over-quarter to $123M.

Based on Acuta Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.